An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

22 Dec 2023 Status changed from recruiting to active, no longer recruiting, according to a Mendus media release.
22 Dec 2023 According to a Mendus media release, this trial is fully recruited with 17 patients. Mendus expects further read outs of the trial in 2024, including a survival analysis in 2024H2.
28 Sep 2023 According to an Immunicum media release, data from the ongoing Phase 1 ALISON trial in ovarian cancer will be presented at the 38th Society for the Immunotherapy of Cancer meeting (SITC 2023),

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com